Grace Therapeutics, Inc. Total Liabilities
Grace Therapeutics, Inc. total liabilities. Based on the latest financial reports, Grace Therapeutics, Inc. (GRCE) has total liabilities worth $3.60 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GRCE cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Grace Therapeutics, Inc. (2010–2025)
Total liabilities of Grace Therapeutics, Inc. from 2010 to 2025. This chart illustrates how Grace Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Grace Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Grace Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Morixe Hermanos SACI
BA:MORI
|
Argentina | AR$58.64 Billion |
|
Aurora Mobile Ltd
NASDAQ:JG
|
USA | $316.94 Million |
|
Ledtech Electronics Corp
TW:6164
|
Taiwan | NT$515.19 Million |
|
Inhome Prime Properties SOCIMI S.A.
MC:YIPP
|
Spain | €112.32K |
|
Atlas Engineered Products Ltd
V:AEP
|
Canada | CA$35.99 Million |
|
Brixton Metals Corporation
V:BBB
|
Canada | CA$3.21 Million |
|
Focus Graphite Inc
V:FMS
|
Canada | CA$3.87 Million |
|
Riverstone Credit Opportunities Income Plc
LSE:RCOI
|
UK | $586.00K |
Liability Composition Analysis (2010–2025)
This chart breaks down Grace Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Grace Therapeutics, Inc. balance sheet assets.
Liquidity & Leverage Metrics
Grace Therapeutics, Inc. Total Liabilities Ratios Explained
Grace Therapeutics, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Grace Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Grace Therapeutics, Inc. (2010–2025)
The table below shows the annual total liabilities of Grace Therapeutics, Inc. from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $5.38 Million | -53.42% |
| 2024-03-31 | $11.56 Million | +3.48% |
| 2023-03-31 | $11.17 Million | -45.12% |
| 2022-03-31 | $20.35 Million | +199.35% |
| 2021-03-31 | $6.80 Million | -31.05% |
| 2020-03-31 | $9.86 Million | -61.86% |
| 2019-03-31 | $25.85 Million | +126.56% |
| 2018-03-31 | $11.41 Million | +1092.12% |
| 2016-03-31 | $957.12K | -69.91% |
| 2015-03-31 | $3.18 Million | -71.35% |
| 2014-03-31 | $11.10 Million | +364.58% |
| 2013-03-31 | $2.39 Million | +88.63% |
| 2012-03-31 | $1.27 Million | -75.83% |
| 2011-03-31 | $5.24 Million | +7.35% |
| 2010-03-31 | $4.88 Million | -- |
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a top… Read more